AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Stock analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of AnaptysBio in a research note issued to investors on Wednesday, February 12th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings per share of ($1.56) for the quarter, down from their prior forecast of ($1.44). HC Wainwright currently has a "Neutral" rating and a $19.00 target price on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio's Q2 2025 earnings at ($1.65) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.85) EPS, FY2025 earnings at ($6.79) EPS, FY2026 earnings at ($6.19) EPS, FY2027 earnings at ($10.60) EPS and FY2028 earnings at ($10.49) EPS.
ANAB has been the topic of several other reports. Wedbush reissued an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a research report on Wednesday, February 12th. UBS Group boosted their price target on AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. Guggenheim decreased their price objective on AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, December 12th. BTIG Research downgraded AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd. Finally, Wolfe Research assumed coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 target price for the company. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, AnaptysBio has an average rating of "Moderate Buy" and a consensus target price of $37.45.
Check Out Our Latest Stock Report on AnaptysBio
AnaptysBio Stock Performance
Shares of NASDAQ ANAB traded down $0.74 during midday trading on Monday, hitting $18.87. 719,150 shares of the stock traded hands, compared to its average volume of 1,160,307. The firm has a market capitalization of $574.21 million and a P/E ratio of -3.10. AnaptysBio has a one year low of $12.21 and a one year high of $41.31. The firm has a 50-day moving average of $15.73 and a two-hundred day moving average of $25.41.
Insider Buying and Selling at AnaptysBio
In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 33.70% of the stock is currently owned by insiders.
Institutional Trading of AnaptysBio
A number of large investors have recently added to or reduced their stakes in ANAB. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of AnaptysBio in the 4th quarter worth $40,000. Values First Advisors Inc. bought a new stake in shares of AnaptysBio in the 3rd quarter worth about $49,000. nVerses Capital LLC increased its holdings in shares of AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock worth $54,000 after buying an additional 1,400 shares during the last quarter. Finally, AlphaQuest LLC raised its position in shares of AnaptysBio by 1,891.5% during the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after buying an additional 4,237 shares in the last quarter.
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
See Also
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
